AR089954A1 - Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico - Google Patents

Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico

Info

Publication number
AR089954A1
AR089954A1 ARP130100412A ARP130100412A AR089954A1 AR 089954 A1 AR089954 A1 AR 089954A1 AR P130100412 A ARP130100412 A AR P130100412A AR P130100412 A ARP130100412 A AR P130100412A AR 089954 A1 AR089954 A1 AR 089954A1
Authority
AR
Argentina
Prior art keywords
methyl
dioxol
triazol
oxo
amino
Prior art date
Application number
ARP130100412A
Other languages
English (en)
Inventor
Rapta Miroslav
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR089954A1 publication Critical patent/AR089954A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Una forma cristalina de ácido (2S,4R)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1H-[1,2,3]triazol-4-carbonil)amino]pentanoico éster 5-metil-2-oxo-[1,3]dioxol-4-ilmetílico o su tautómero. También se provee composiciones farmacéuticas que comprende el compuesto cristalino, procesos e intermediarios para preparar el compuesto cristalino, y su uso para tratar enfermedades. Reivindicación 1: Éster 5-metil-2-oxo-[1,3]dioxol-4-ilmetílico del ácido (2S,4R)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1H-[1,2,3]triazol-4-carbonil)amino]pentanoico cristalino, caracterizado porque tiene un patrón de difracción de rayos X en polvo que comprende picos de difracción en valores 2q de 8,62 ± 0,20, 9,50 ± 0,20, 12,14 ± 0,20, 15,18 ± 0,20, 15,72 ± 0,20, 19,90 ± 0,20, 20,40 ± 0,20, 23,42 ± 0,20, y 25,70 ± 0,20.
ARP130100412A 2012-02-15 2013-02-08 Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico AR089954A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261599023P 2012-02-15 2012-02-15

Publications (1)

Publication Number Publication Date
AR089954A1 true AR089954A1 (es) 2014-10-01

Family

ID=47790519

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100412A AR089954A1 (es) 2012-02-15 2013-02-08 Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico

Country Status (4)

Country Link
US (1) US8933111B2 (es)
AR (1) AR089954A1 (es)
TW (1) TW201336839A (es)
WO (1) WO2013123165A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103380119B (zh) 2011-02-17 2016-02-17 施万生物制药研发Ip有限责任公司 作为脑啡肽酶抑制剂的经取代的氨基丁酸衍生物
CN109456212A (zh) * 2018-12-03 2019-03-12 康化（上海）新药研发有限公司 一种沙库比曲中间体的合成方法
MX2022003408A (es) * 2019-09-20 2022-07-12 Shenzhen Salubris Pharm Co Ltd Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia cardiaca.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
ES2582395T3 (es) 2009-05-28 2016-09-12 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
ME01923B (me) 2009-05-28 2015-05-20 Novartis Ag Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
CN103380119B (zh) * 2011-02-17 2016-02-17 施万生物制药研发Ip有限责任公司 作为脑啡肽酶抑制剂的经取代的氨基丁酸衍生物

Also Published As

Publication number Publication date
TW201336839A (zh) 2013-09-16
US8933111B2 (en) 2015-01-13
US20130209505A1 (en) 2013-08-15
WO2013123165A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
HK1195312A1 (zh) 用於治療變性疾病和炎性疾病的新化合物
BR112012027509A8 (pt) Composto pirazolil-quinoxalina inibidor de quinase, combinação, produto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e método
IN2015KN00262A (es)
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MX353847B (es) Composicion farmaceutica de rosuvastatina calcica.
AU2014224456A8 (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
PL2588621T3 (pl) Sposób wytwarzania butanolu lub acetonu
MX362879B (es) Usos novedosos.
GT201300064A (es) Monohidrato de derivados de aza-adamantano
WO2009118589A3 (en) Orally disintegrating compositions of rhein or diacerein
MY163236A (en) Polyethylene glycol-containing composition
AR089954A1 (es) Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico
AP2012006645A0 (en) Pharmaceutical compositions comprising paracetamoland process for preparing the same
MX2013012773A (es) Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
IL245260B (en) Non-aqueous crystalline form of cabazitaxel, process for its preparation and pharmaceutical compositions thereof
WO2011095985A3 (en) Rasagiline salts and processes for the preparation thereof
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2014147504A3 (en) Process for preparation of 2-chloro-n-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
ZA201501280B (en) Use of substituted 2,3-dihydro-1-benzofuran-4-carboxylic acids or salts thereof as active substances against abiotic plant stress
WO2014076616A3 (en) Formulations of 5-azacytidine

Legal Events

Date Code Title Description
FB Suspension of granting procedure